Uzedy (Risperidone) Patent Expiration, LOE Window & CMS Spending

Uzedy (Risperidone) by Teva Pharmaceuticals: FDA Orange Book LOE 2042-03-17, 22 AB generics, $155.8M 2024 CMS Part D & Medicaid spend, and $6,160 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN213586 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-03-17
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors22
2024 CMS Total Public Spend$155.8M
2024 Medicare Part D Spend$65.3M
2024 Medicaid Spend$90.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,160 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.